epileptic: Dose calibration of anti-epileptic drugs data

In joineR: Joint Modelling of Repeated Measurements and Time-to-Event Data

Dose calibration of anti-epileptic drugs data

Description

The SANAD (Standard and New Anti-epileptic Drugs) study (Marson et al., 2007) is a randomized control trial of standard and new anti-epileptic drugs, comparing effects on longer term clinical outcomes. The data consists of longitudinal measurements of calibrated dose for the groups randomized to a standard drug (CBZ) and a new drug (LTG). The objective of the analysis is to investigate the effect of drug titration on the relative effects of LTG and CBZ on treatment failure (withdrawal of the randomized drug). There are several baseline covariates available, and also data on the time to withdrawal from randomized drug.

Usage

data(epileptic)

Format

This is a data frame in the unbalanced format, that is, with one row per observation. The data consists of columns for patient identifier, time of measurement, calibrated dose, baseline covariates, and survival data. The column names are identified as follows:

id

integer: patient identifier.

dose

numeric: calibrated dose.

time

integer: timing of clinic visit at which dose recorded (days).

with.time

integer: time of drug withdrawal/maximum follow up time (days).

with.status

censoring indicator (1 = withdrawal of randomized drug and 0 = not withdrawn from randomized drug/lost to follow up).

with.status2

censoring indicator (1 = withdrawal of randomized drug due to inadequate seizure control, (2 = withdrawal of randomized drug due to unacceptable adverse effects, and 0 = not withdrawn from randomized drug/lost to follow up).

with.status.uae

1 = withdrawal due to unacceptable adverse effects, 0 = otherwise.

with.status.isc

1 = withdrawal due to inadequate seizure control, 0 = otherwise.

treat

factor: randomized treatment (CBZ or LTG).

age

numeric: age of patient at randomization (years).

gender

factor: gender of patient. F = female, M = male.

learn.dis

factor: learning disability.

Source

SANAD Trial Group, University of Liverpool

References

Marson AG, Appleton R, Baker GA, et al. A randomised controlled trial examining longer-term outcomes of standard versus new antiepileptic drugs. The SANAD Trial. Health Tech Assess. 2007; 11(37).

Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet. 2007; 365: 2007-2013.

Williamson PR, Kolamunnage-Dona R, Philipson P, Marson AG. Joint modelling of longitudinal and competing risks data. Stats Med. 2008; 27(30): 6426-6438.

See Also

heart.valve, liver, mental, aids.

joineR documentation built on Jan. 23, 2023, 5:39 p.m.